Lineage Cell Therapeutics
LCTX
124 hedge funds and large institutions have $182M invested in Lineage Cell Therapeutics in 2021 Q4 according to their latest regulatory filings, with 25 funds opening new positions, 27 increasing their positions, 39 reducing their positions, and 16 closing their positions.
457% more call options, than puts
Call options by funds: $1.61M | Put options by funds: $289K
56% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 16
8% more funds holding
Funds holding: 115 → 124 (+9)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
1.15% less ownership
Funds ownership: 45.28% → 44.13% (-1.2%)
5% less capital invested
Capital invested by funds: $192M → $182M (-$9.76M)
31% less repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 39
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$3.41M |
| 2 |
RA
Raffles Associates
New York
|
+$1.05M |
| 3 |
Morgan Stanley
New York
|
+$944K |
| 4 |
Millennium Management
New York
|
+$734K |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
+$714K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$7.92M |
| 2 |
JP Morgan Chase
New York
|
-$2.18M |
| 3 |
Northern Trust
Chicago,
Illinois
|
-$975K |
| 4 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$913K |
| 5 |
Rafferty Asset Management
New York
|
-$488K |
LCTX Hedge Fund Activity: Q4 2021 in Review
124 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in Lineage Cell Therapeutics (LCTX) for Q4 2021, worth a combined $182M — down 5.1% from $192M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new LCTX positions and 16 closed out — a net gain of 9 holders — while 27 added to existing stakes and 39 trimmed.
The largest buyer was BlackRock, adding an estimated $3.41M. The largest seller was State Street, cutting an estimated $7.92M.
- 124 institutional investors held Lineage Cell Therapeutics (LCTX) as of Q4 2021, up from 115 in Q3 2021.
- Funds reported $182M of Lineage Cell Therapeutics stock for Q4 2021, down 5.1% quarter-over-quarter.
- 25 funds opened new Lineage Cell Therapeutics positions in Q4 2021 and 16 closed out, a net change of +9 holders.
- The largest Lineage Cell Therapeutics buyer in Q4 2021 was BlackRock, an estimated $3.41M added.
- The largest Lineage Cell Therapeutics seller in Q4 2021 was State Street, an estimated $7.92M sold.
Based on aggregated 13F filings for Q4 2021.